GSK plc (GLAXF)
| Market Cap | 73.47B |
| Revenue (ttm) | 40.74B |
| Net Income (ttm) | 4.07B |
| Shares Out | n/a |
| EPS (ttm) | 0.98 |
| PE Ratio | 18.03 |
| Forward PE | 7.89 |
| Dividend | 0.74 (3.88%) |
| Ex-Dividend Date | May 15, 2025 |
| Volume | 5,939 |
| Average Volume | 3,609 |
| Open | 18.50 |
| Previous Close | 18.00 |
| Day's Range | 18.50 - 18.50 |
| 52-Week Range | 15.54 - 23.00 |
| Beta | 0.27 |
| RSI | 53.77 |
| Earnings Date | Apr 28, 2025 |
About GSK plc
GSK plc, together with its subsidiaries, engages in the research, development, and manufacture of vaccines, and specialty and general medicines to prevent and treat disease in the United Kingdom, the United States, and internationally. It operates through two segments, Commercial Operations and Total R&D. The company offers shingles, meningitis, respiratory syncytial virus, infectious, polio, influenza, and pandemic vaccines. It also provides medicines for HIV, oncology, respiratory/immunology, inflammation, and other specialty medicine product... [Read more]
Financial Performance
In 2024, GSK plc's revenue was 31.38 billion, an increase of 3.46% compared to the previous year's 30.33 billion. Earnings were 2.58 billion, a decrease of -47.75%.
Financial numbers in GBP Financial StatementsNews
iTeos Therapeutics: End To Belrestotug Program Leads To A Hold Rating
iTeos Therapeutics downgraded to Hold after belrestotug failure and GSK deal ending. Read my updated analysis on ITOS stock here.
GSK To Buy Phase-3 Ready Liver Disease Drug For Up To $2 Billion
GSK plc (NYSE: GSK) on Wednesday agreed to acquire Boston Pharmaceuticals’ lead asset, efimosfermin alfa . Under the agreement, GSK will pay up to $2 billion in total cash consideration. This include...
GSK to buy phase III-ready drug efimosfermin from Boston Pharmaceuticals for as much as $2B
GSK Buys Liver-Disease Treatment From Boston Pharmaceuticals for Up to $2 Billion
The pharma giant will pay $1.2 billion up-front for efimosfermin, with deal including potential success-based milestone payments of $800 million.
GSK to buy efimosfermin for up to $2 billion
British pharmaceutical giant GSK on Wednesday said it will buy efimosfermin, a phase III-ready potential specialty medicine from Boston Pharmaceuticals, for up to $2 billion.
GSK to acquire efimosfermin, a phase III-ready potential best-in-class specialty medicine to treat and prevent progression of steatotic liver disease (SLD)
CAMBRIDGE, Mass.--(BUSINESS WIRE)--GSK plc (LSE/NYSE: GSK) and Boston Pharmaceuticals, a leading clinical stage biopharmaceutical company developing highly targeted therapies for patients with serious...
FTSE 100 Live 14 May: GSK unveils $2bn acquisition, Imperial Brands posts results
GSK Pharma share price jumps 5% as Q4 EBITDA rises 29.5% YoY to Rs 333.2 crore
GSK Pharma’s shares surged 5% following the release of its Q4 FY25 financial results. The company’s consolidated revenue for the quarter increased by 4.8%, reaching Rs 974.4 crore compared to Rs 929.8...
iTeos Stock Soars Despite Trial Setback On Liquidation Buzz And Solid Cash Pile
iTeos ends belrestotug program with GSK after Phase ... Full story available on Benzinga.com
ITeos, GSK discontinue lung cancer therapy development
iTeos Therapeutics and partner GSK said on Tuesday that they terminated the development of their experimental lung cancer therapy after its failure to significantly improve progression free survival i...
GSK, iTeos end lung cancer asset development after trial failure
India's GlaxoSmithKline Pharma reports profit rise on strong demand
India's GlaxoSmithKline Pharmaceuticals reported a higher fourth-quarter profit on Tuesday, led by steady demand for its generic drugs.
AstraZeneca and GSK in the firing line as Trump targets big pharma: ALEX BRUMMER
No one expected US peace in our time at the Geneva talks with China at the weekend, but what emerged is better than predicted.
Trump wants to slash U.S. drug prices with 'most favored nation' policy – here's what to know
President Donald Trump wants to lower U.S. drug costs by linking prices to those paid in other developed countries – a move that experts say could face a challenging path to becoming a reality. Trump...
Dr. Scott Gottlieb: What to expect from President Trump's executive order to lower drug prices
Scott Gottlieb, former FDA commissioner, joins CNBC's 'Squawk on the Street' to discuss how the White House may plan to cut drug prices.
Global Pharma Stocks Fall as Trump Plans to Cut Drug Prices
Novo Nordisk, which generates around 60% of its sales in the U.S., is among the biggest losers in early European trade.
Pharmaceutical stocks slide as Trump vows to cut US prescription drug prices ‘by 30-80%'
President plans to use executive powers, saying US should pay ‘same price as nation that pays the lowest price'
GSK and Lifetime® launch original movie to raise awareness about the impact of meningitis
PHILADELPHIA--(BUSINESS WIRE)-- #Adolescents--GSK and Lifetime® launch original movie to raise awareness about the impact of meningitis.
GSK met main goal in liver disease treatment trial
EU drugs regulator confirms suicidal thoughts as side effect of anti hair-loss drug
The European drugs regulator said on Thursday its safety committee has confirmed suicidal thoughts as a side effect of Organon's anti hair-loss drug finasteride, following an EU-wide review of availab...
New vaccine chief rocks pharmaceutical stocks
CNBC's Angelica Peebles joins 'Squawk on the Street' to discuss how the biotech and pharma industry is reacting to a new FDA chief of vaccines appointed by President Trump.
Pfizer, GSK RSV shot recommendations under scrutiny from RFK Jr. aide - report
5 Reasons GSK Looks Good
GSK declares $0.4216 dividend
Blueprint Medicines Reports First Quarter 2025 Results and Raises AYVAKIT®/AYVAKYT® (avapritinib) Full Year Revenue Guidance
-- Achieved 61% year-over-year growth with $149.4 million in AYVAKIT net product revenues in the first quarter 2025 -- -- Raising AYVAKIT net product revenue guidance to $700 - $720 million for 2025 -...